| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 11, 2014 | ImaginAb Raises $21M in Series B Funding | ImaginAb, an Inglewood, CA-based clinical stage biotech company, raised $21m in Series B funding.
The round was led by Mérieux Développement, with participation from Novartis Venture Funds, Cycad Group and Nextech Invest.
The company intend... |
| May 9, 2014 | Anokion Closes $37.5M Series A Financing Round | Anokion SA, a Lausanne, Swuitzerland-based developer of a technology for retraining white blood cells to induce therapeutic immune tolerance, closed a CHF33m (approximately $37.5m) Series A financing round.
The round was co-led by Novartis ... |
| May 5, 2014 | Swiss biotech start-up Anokion closes financing round for CHF 33 Million | |
| Feb 24, 2014 | Thesan Pharmaceuticals Closes $49M Series B Financing | Thesan Pharmaceuticals, a Carlsbad CA-based developer of novel approaches for the treatment of dermatological disorders, closed a $49m Series B financing.
The round was led by current investor Novo Ventures with participation from SV Life S... |
| Dec 9, 2013 | Covagen Secures CHF 42 Million in Series B Financing | |
| Aug 21, 2013 | Q2 Corporate VC healthcare deals, funding both up more than 30 percent | Corporate venture capital may be what fills in the large gaps VC has left behind, with CVC deals about 60 percent larger than VC deals on the whole. Healthcare corporate venture capital deals are up nearly 40 percent compared to Q1 and fund... |
| May 29, 2013 | GSK acquires Okairos AG for EUR 250 mio | |
| May 20, 2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing.
Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| May 20, 2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financing | eFFECTOR Therapeutics Raises $45 Million in Series A Financing
Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer
San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutic... |
| May 15, 2013 | Tokai Pharmaceuticals Raises $35.5M in Series E Financing | Tokai Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biopharmaceutical company focused on developing new treatments for prostate cancer, raised $35.5m in a Series E financing.
Backers included Apple Tree Partners and Novartis Ventu... |
| Apr 29, 2013 | Opsona Therapeutics Raises €33M in Series C Financing | Opsona Therapeutics, a Dublin, Ireland-based developer of new treatments for inflammatory diseases, raised €33m (US$43m) in Series C financing.
The round was led by BB Biotech Ventures and Novartis Venture Fund, with participation from new ... |
| Apr 10, 2013 | Advanced Animal Diagnostics Closes $6M Tranche of Series B Financing | Advanced Animal Diagnostics (AAD), a Durham, NC-based developer of on-farm diagnostics to improve animal health and productivity, closed a $6m tranche of Series B financing.
Backers included Intersouth Partners, Novartis Venture Funds and p... |
| Dec 11, 2012 | Biotechnology startup raises $11M for small molecule therapeutic to treat cancer, fibrosis | Galera Therapeutics‘ superoxide dismutase mimetics are small molecules that mimic the effect of the superoxide dismutase enzyme’s properties. Newly appointed CEO Dr. Mel Sorensen told MedCity News in a phone interview that the technology wa... |
| Dec 11, 2012 | Galera Therapeutics Raises $11M in Series A Venture Capital Financing | Galera Therapeutics, Inc., a Malvern, PA-based biotechnology company focused on the development of drugs targeting oxygen metabolic pathways, has raised $11m in Series A venture capital financing.
The round was co-led by New Enterprise Asso... |
| Nov 15, 2012 | Corporate Venturing is gaining in importance in the biotech industry | Researchers at the ETH Zurich have conducted a global study (Corporate Venturing Research Initiative) of 48 leading corporate venture units in collaboration with management consultancy Bain & Company in Boston. The results were publishe... |
| Oct 31, 2012 | Thesan Pharmaceuticals Closes $16M Series A Financing | Thesan Pharmaceuticals, a San Clemente CA-based biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions, has closed a $16m Series A financing.
The round was co-led... |
| Oct 19, 2012 | Neurovance Closes $7M Series A1 Funding | Neurovance, Inc., a Cambridge, Massachusetts-based a spinout of Euthymics Bioscience, Inc., has closed a $7m Series A1 round.
The investment was led by existing investor Novartis Venture Fund, with participation from existing investors Vent... |
| Mar 27, 2012 | ImaginAb Completes $12.5M Series A Financing | ImaginAb, Inc., a Los Angeles, CA-based clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, completed a $12.5m Series A financing.
The round was led by Novar... |
| Mar 16, 2012 | Drugmaker targets riboswitches to combat antibiotic-resistant diseases | In 2010, BioRelix entered a research collaboration agreement with a subsidiary of Merck & Co Inc. to identify new antibacterial drug candidates.
According to the company’s recent U.S. Security and Exchange Commission filing, the $2.5 mi... |
| Feb 20, 2012 | Are new life science investors eyeing Research Triangle Park? | Plus, the recent CED Life Science Conference had a series of new investor faces in the audience, as well as some prodigal sons. A few I spoke with said they were there because they thought there were deals to be done that the typical Park i... |
| Jul 20, 2011 | Atlas Genetics Raises £16.9M in Series B Funding | Atlas Genetics Ltd, a Bristol, UK-based diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, has raised £16.9m in Series B funding.
Investors include Novartis Venture Funds, and Consort Medical, ... |
| Jul 5, 2011 | MyoPowers Medical Technologies Closes CHF16M Series B Financing Round | MyoPowers Medical Technologies SA, a Lausanne, Switzerland-based medical device company developing artificial muscle technologies to treat sphincter dysfunction and incontinences, has closed a CHF 16m Series B financing round.
The round was... |
| Apr 10, 2011 | Corporate Venture Funds: What’s the Deal? | Covidien Ventures
Covidien Ventures was formed in 2008 with the mission to “…invest in areas of strategic importance to the Company with the goal of providing early exposure to innovative technologies and enhancing market intelligence in he... |
| Mar 16, 2011 | Diagnostics company AAD raises $11 million B round | Diagnostic device company Advanced Animal Diagnostics has secured $11 million in a series B round, which the company will pour into continued research and development of a detection tool for mastitis in dairy cows.
The round was led by Inte... |
| Mar 15, 2011 | NC diagnostics device company AAD raises $11M in series B round | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Nov 11, 2009 | Cellerix levanta €27M en el 1º cierre de la 2ª ronda liderada por Ysios, LSP y Ventech | 11/11/ 2009
Nota de prensa
CELLERIX LEVANTA €27 MILLONES EN EL PRIMER CIERRE DE LA 2ª RONDA LIDERADA POR YSIOS, LSP Y VENTECH.
Cellerix, empresa biofarmacéutica líder en la producción y desarrollo de medicamentos innovadores basados en e... |
| Oct 13, 2009 | Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment | Akebia is in a race to develop its drug against other treatments supported by the likes of GlaxoSmithKline and Takeda Pharmaceuticals that are further along in their trials. The company thinks it can make up ground. Plus, even if it isn’t f... |
| Aug 17, 2009 | Portaero still looking for $182K to treat emphysema | Portaero, developer of a device used to treat chronic obstructive pulmonary diseases — particularly emphysema — has raised the bulk of its targeted $12 million round of equity, according to regulatory filings. It is still short $182,000. Ba... |
| Jul 29, 2009 | Cardiovascular biopharma Akebia takes additional funding to develop 2 drugs | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Jun 30, 2009 | Oncology drugmaker ProCertus closes on $2.1 million | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| Jun 12, 2009 | Anti-viral developer Alios raises $8M more for $32M | Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the ... |
| Feb 10, 2009 | Alios nabs $8.4M to treat viruses | South San Francisco-based Alios BiopPharma just brought in $8.4 million in first-round funding from Novo, Novartis BioVentures and Roche Finance, according to peHUB. The company develops treatments for viruses by activating various parts of... |
| Jan 30, 2009 | Hearing aid maker Sonitus lands $13.5M | Sonitus Medical, a company that makes a hearing device to treat single-sided deafness, just brought in $13.5 million in second-round funding to commercialize its flagship product, reports VentureWire. Based in San Mateo, Calif., it still ne... |
| Jan 7, 2009 | Intradigm closes $21.4M for cancer therapeutics | Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
... |
| Dec 4, 2008 | Catalyst lands $40M to combat disease-causing proteins | Catalyst Biosciences has raked in $40.4 million in third-round funding to continue engineering an enzyme called protease to fight disease-causing proteins. The technology has the potential to affect many different diseases, including cancer... |
| Oct 24, 2008 | Phenomix cancels IPO, finds new lab partner | Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Fo... |
| Oct 3, 2008 | Intradigm lands $18.5M to advance oncology treatment | Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Ventu... |
| Jul 19, 2007 | Ablation Frontiers raises $22M for treating arrythmia | Ablation Frontiers, a Carlsbad, Calif., developer of devices for treating irregular heartbeats known as cardiac arrythmias, raised $21.8 million in a third funding round. The Novartis Venture Fund led the round, joined by Affinity Ventures,... |
| Jun 19, 2007 | Adenosine Therapeutics seeks $14M for new drugs | Adenosine Therapeutics, a Charlottesville, Va., biotech developing drugs that target forms of a cell-surface protein called the adenosine receptor, is raising $14 million in a third funding round. The round is being led by the Novartis Opti... |
| Jun 19, 2007 | Cequent Pharma raises $9 million for RNAi | Cequent Pharmaceuticals, a Cambridge, Mass., developer of drugs based on a new gene-silencing technology, raised $9 million in a first-round funding. The round was led by the Novartis Option Fund, joined by Ampersand Ventures, Nexus Medical... |
| Jun 7, 2007 | Aileron Therapeutics pulls in $7M for peptide therapies | Aileron Therapeutics, a Cambridge, Mass., developer of peptide-based drugs for cancer, raised $7 million in a second funding round. The company is at work on a new class of “stapled” peptides, or protein fragments, that it says can penetrat... |
| Jun 5, 2007 | Antibiotic maker BioRelix gets $26M | BioRelix, a New Haven, Conn., developer of new antibiotics, raised $25.75 million in a first funding round, VentureWire reports (subscription required). The round included New Leaf Venture Partners, Aisling Capital, CHL Medical Partners, No... |
| May 11, 2007 | ProCertus pulls in $2.3M for prevention of chemo, radiation side effects | ProCertus BioPharm, a Madison, Wis., company developing drugs to minimize the side effects of radiation and chemotherapy, raised $2.3 million in a first round of financing. The company will use the money to begin human tests of products suc... |
| Q2 Corporate VC healthcare deals, funding both up more than 30 percent | Corporate venture capital may be what fills in the large gaps VC has left behind, with CVC deals about 60 percent larger than VC deals on the whole. Healthcare corporate venture capital deals are up nearly 40 percent compared to Q1 and fund... |
| Are new life science investors eyeing Research Triangle Park? | Look for new dealflow, new investor faces and new funds in Research Triangle Park throughout the year.
At the moment, the life science investing opportunities can look pretty dry. Intersouth Partners, a Durham, North Carolina venture capita... |
| NC diagnostics device company AAD raises $11M in series B round | Diagnostic device company Advanced Animal Diagnostics has secured $11 million in a series B round of equity financing that the company will pour into continued research and development of a detection tool for mastitis in dairy cows.
The rou... |
| Corporate Venture Funds: What’s the Deal? | For many big medical device companies, awash in cash and hungry for innovation, the decision to form a venture arm seems a natural one. No need to hassle with raising a fund or deal with demanding LPs; just hang out a shingle, set aside a r... |
| Biotechnology startup raises $11M for small molecule therapeutic to treat cancer, fibrosis | A biotechnology startup has figured out a way to harness a natural antioxidant defense for cells and apply it to treating conditions ranging from mucositis — a common side effect of chemotherapy and radiation therapy for head and neck cance... |
| Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment | CINCINNATI, Ohio — As Procter & Gamble started the slow dismantling of its pharmaceutical division three years ago, Akebia Therapeutics was there to pick up some pieces.
At that time, Akebia was largely Joseph Gardner –Â who was leaving... |
| Drugmaker targets riboswitches to combat antibiotic-resistant diseases | As long-trusted antibiotics encounter increased resistance by the bacterial pathogens they were originally designed to kill, the need for novel anti-infective drug treatments is mounting. One young company has just raised $2.5 million to co... |
| Oncology drugmaker ProCertus closes on $2.1 million | MADISON, Wisconsin — ProCertus BioPharm will use $2.1 million in private investment to start several clinical trials on drugs that fight the side effects of radiotherapy and chemotherapy.
The oncology drugmaker also said Tuesday it has star... |
| Cardiovascular biopharma Akebia takes additional funding to develop 2 drugs | CINCINNATI, Ohio — Cardiovascular drugmaker Akebia Therapeutics will add $10 million more than expected to its Series A fund-raise, bringing the total to $25 million, the company stated (pdf).
The company stated it raised additional money t... |